

## NEW GRANT PROGRAM ANNOUNCEMENT

### Novel Biomarkers 2017

### Neurodegenerative Diseases of Aging

<b>Program information webinar:</b>	23 March 2017, 3:00 pm GMT
<b>Letter of Intent deadline:</b>	19 April 2017, 4:00 pm BST
<b>Proposal deadline:</b>	8 September 2017, 4:00 pm BST
<b>Anticipated award notification:</b>	November 2017

### Program Information

The prevalence of neurodegenerative diseases of aging is high and growing rapidly, and meeting this challenge requires pioneering approaches to accelerating treatments. The **Novel Biomarkers 2017** program supports high-risk, high-reward, translational research projects on novel biomarkers.

**Goal:** To support testing novel biomarkers in clinical samples/data or patients to accelerate the development of therapeutics for neurodegenerative diseases of aging.

### Funding per Project

Up to £333,000 (UK) or €390,000 (Ireland), over up to 3 years.

#### Institute definition of neurodegenerative diseases of aging:

- Alzheimer's disease
- Parkinson's disease
- Frontotemporal dementia
- Dementia with Lewy bodies
- Multiple system atrophy
- Progressive supranuclear palsy
- Vascular contributions to the above diseases
- Prodromes to the above diseases

### Biomarker Eligibility

- To be considered novel, biomarkers should be underfunded and/or less studied.
- Biomarkers should be for disease diagnosis, prognosis, for stratification to clinical trials, or to predict response to therapies.
- Biomarkers should measure pathology of the disease (e.g., fluid, imaging or tissue biopsy derived biomarkers), and not be based on cognitive, neuropsychological or behavioural phenotypes (e.g., gait, grip strength, and cognitive tests).
- Pilot data should be included to justify testing in clinical samples/data or patients.
- Genetic determinants and predispositions are not in scope.
- Biomarker discovery and unbiased screening approaches are not in scope.

### Applicant Eligibility

Principal Applicants must be at or above the level of Lecturer (Assistant Professor or equivalent) and hold an appointment at the institution from which they are applying.

Institutions must be either a UK-registered charity or registered with the Charities Regulatory Authority in Ireland. We may also be able to accept applications from qualified institutions in the UK or Ireland meeting the public benefit requirement towards research in neurodegenerative diseases of aging; please contact us before applying.

Apply <https://weston.smartsimple.ca/welcome/neuroscience>

More information <http://westonbraininstitute.ca/novel-biomarkers-2017/>

[neuro@weston.ca](mailto:neuro@weston.ca) | +1-416-935-4056